WHO ICTRP trial
The effect of Celecoxib on depression in patients with COVID-19
IRCT20090117001556N142 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20090117001556N142 |
|---|---|
| Public title | The effect of Celecoxib on depression in patients with COVID-19 |
| Scientific title | Investigating the effect of Celecoxib on depression induced by COVID-19: A randomized double blind and placebo controlled clinical trial |
| Primary sponsor | Tehran University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 2-3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | COVID-19. COVID-19, virus identified;U07.1 |
| Interventions | Intervention 1: Intervention group: Patients treated with Celecoxib 100 mg BID for 6 weeks. Intervention 2: Control group: Patients treated with placebo BID for 6 weeks. |
| Registration date | Mar 1, 2022 |
| Target size | 50 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: